Correlation Between Acrivon Therapeutics, and Eliem Therapeutics
Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and Eliem Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and Eliem Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Acrivon Therapeutics, Common and Eliem Therapeutics, you can compare the effects of market volatilities on Acrivon Therapeutics, and Eliem Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of Eliem Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and Eliem Therapeutics.
Diversification Opportunities for Acrivon Therapeutics, and Eliem Therapeutics
0.31 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Acrivon and Eliem is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and Eliem Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eliem Therapeutics and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with Eliem Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eliem Therapeutics has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and Eliem Therapeutics go up and down completely randomly.
Pair Corralation between Acrivon Therapeutics, and Eliem Therapeutics
Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to generate 0.83 times more return on investment than Eliem Therapeutics. However, Acrivon Therapeutics, Common is 1.2 times less risky than Eliem Therapeutics. It trades about -0.22 of its potential returns per unit of risk. Eliem Therapeutics is currently generating about -0.36 per unit of risk. If you would invest 806.00 in Acrivon Therapeutics, Common on August 24, 2024 and sell it today you would lose (162.00) from holding Acrivon Therapeutics, Common or give up 20.1% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Acrivon Therapeutics, Common vs. Eliem Therapeutics
Performance |
| Timeline |
| Acrivon Therapeutics, |
| Eliem Therapeutics |
Acrivon Therapeutics, and Eliem Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Acrivon Therapeutics, and Eliem Therapeutics
The main advantage of trading using opposite Acrivon Therapeutics, and Eliem Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, Eliem Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will offset losses from the drop in Eliem Therapeutics' long position.| Acrivon Therapeutics, vs. Aerovate Therapeutics | Acrivon Therapeutics, vs. Adagene | Acrivon Therapeutics, vs. Rezolute | Acrivon Therapeutics, vs. AN2 Therapeutics |
| Eliem Therapeutics vs. Pmv Pharmaceuticals | Eliem Therapeutics vs. MediciNova | Eliem Therapeutics vs. Pharvaris BV | Eliem Therapeutics vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Complementary Tools
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |